Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Change in Accured Expenses: 2023-2025

Historic Change in Accured Expenses for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to -$2.3 million.

  • Compass Therapeutics' Change in Accured Expenses rose 46.46% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 million, marking a year-over-year increase of 311.44%. This contributed to the annual value of $3.8 million for FY2024, which is 141.12% up from last year.
  • According to the latest figures from Q3 2025, Compass Therapeutics' Change in Accured Expenses is -$2.3 million, which was down 3.87% from -$2.2 million recorded in Q2 2025.
  • In the past 5 years, Compass Therapeutics' Change in Accured Expenses registered a high of $6.9 million during Q1 2025, and its lowest value of -$4.3 million during Q3 2024.
  • Its 3-year average for Change in Accured Expenses is -$273,273, with a median of -$2.2 million in 2023.
  • Data for Compass Therapeutics' Change in Accured Expenses shows a peak YoY increase of 1,090.99% (in 2025) and a maximum YoY decrease of 141.06% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Compass Therapeutics' Change in Accured Expenses stood at -$3.1 million in 2023, then spiked by 207.70% to $3.4 million in 2024, then spiked by 46.46% to -$2.3 million in 2025.
  • Its last three reported values are -$2.3 million in Q3 2025, -$2.2 million for Q2 2025, and $6.9 million during Q1 2025.